Heterocyclic Building Blocks-Tetrahydropyrans

585-88-6, Maltitol is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Namely, the procedure of the above Synthetic Example 1 was repeated except that 50 g of maltitol was dissolved in 200 ml of water. Thus 45 g of purified maltitol phosphate disodium salt was obtained., 585-88-6

The synthetic route of 585-88-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Kao Corporation; US5409705; (1995); A;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.2081-44-9,Tetrahydro-2H-pyran-4-ol,as a common compound, the synthetic route is as follows.

A. 4-(4-methylphenylsuIfonyloxy)tetrahydropyran: Add TsCl (22.33 g, 117.1 mmol) and DMAP (0.55 g, 4.5 mmol) to a mixture of 4-hydroxytetrahydropyran (9.2 g, 90.08 mmol), pyridine (10.93 ml, 135.12 mmol), and methylene chloride (180 ml). Stir the mixture for 7 days, then add hexanes (360 ml), and filter. Collect the filtrate and wash it sequentially with 5N HCl, and brine. Dry over MgSC>4, remove the solids by filtration and concentrate the filtrate Purify by silica gel chromatography (5-30% methylene chloride/hex) to give the product as an oil (20.75 90%). 1HNMR (CDCl3): delta 1.70-1.91 (m, 4H), 2.47 (s, 3H), 3.48 (m, 2H), 3.86 (m, 2H), 4.65 (m, IH), 7.35 (d, 2H, 8.8 Hz), 7.80 (d, 2H, 8.8 Hz).

2081-44-9, As the paragraph descriping shows that 2081-44-9 is playing an increasingly important role.

Reference£º
Patent; ELI LILLY AND COMPANY; WO2007/87488; (2007); A2;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.14774-37-9,Tetrahydropyran-4-methanol,as a common compound, the synthetic route is as follows.

General procedure: A stirred solution of 4-(2-hydroxyethyl)-morpholine (2.5mL, 20.7mmol) and Et3N (8.6mL, 62.0mmol) in anhydrous DCM (48mL) under N2 was cooled to 0C and then methanesulfonyl chloride (2.4mL, 31.0mmol) was added dropwise. The mixture was stirred at rt for 2h, filtered, the solid washed with minimal DCM and this filtrate combined with the original filtrate was evaporated under reduced pressure to give a yellow oil (10.24g) as a mixture of the desired product 2-(morpholin-4-yl)ethyl methanesulfonate and a salt (Et3NH+Cl+). This material was used without further purification. A stirred solution of 5-benzyloxyindole (600mg, 2.7mmol) in anhydrous DMF (11mL) under N2 was cooled to 0C, and then NaH (60% by mass dispersion in mineral oil; 358mg, 9.0mmol) was added. The mixture was stirred at 0C for 10min and then at rt for 30min. The reaction mixture was cooled to 0C and a solution of 2-(morpholin-4-yl)ethyl methanesulfonate (1.13g, 5.4mmol) in anhydrous DMF (5mL) was added. The mixture was stirred at 45C for 2h, cooled to rt, diluted with EA (20mL) and quenched with sat. aq. NH4Cl (20mL) and H2O (10mL). The layers were separated and the aqueous layer extracted with EA (3¡Á20mL). The combined organics were washed with H2O (4¡Á70mL), dried over MgSO4, filtered and evaporated under reduced pressure. The crude product was purified using flash silica column chromatography (2:1PE:EA) to yield the desired 7a (690mg, 2.1mmol, 76%) as a light brown wax (Rf 0.13, 2:1PE:EA).

14774-37-9, As the paragraph descriping shows that 14774-37-9 is playing an increasingly important role.

Reference£º
Article; Cooper, Anna G.; MacDonald, Christa; Glass, Michelle; Hook, Sarah; Tyndall, Joel D.A.; Vernall, Andrea J.; European Journal of Medicinal Chemistry; vol. 145; (2018); p. 770 – 789;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5631-96-9,2-(2-Chloroethoxy)tetrahydro-2H-pyran,as a common compound, the synthetic route is as follows.

EXAMPLE 1 LL- (4- [2- (2-HYDROXYETHOXY) ETHYL]-L- piperazinyl) dibenzo (b, f] [1, 4] thiazepine (base Quetiapine) To 26.2 mL of 50% aqueous solution of sodium hydroxide are added successively 5 G (14.7 mmols) de 2- (4- dibenzo [b, f] [1, 4] THIAZEPINE-11-IL-PIPERAZINE-L-IL) ethanol, 10.43 g (63.4 mmols) of 2- (2-CHLOROETHOXY)-TETRAHYDRO-2H- pyrane and 0. 49 g of tetrabutyl ammonium hydrogen sulphate. The mixture is heated at 60C for 6 hours with thorough stirring. It is cooled to 20-25C, and 45 mL de toluene and 26 mL of water are added while agitating. The phases are separated and the organic phase is washed with water (2 x 26 ML). 32 mL of water and 5 mL of 35% hydrochloric acid 35% are added and the two-phase mixture is stirred at 20-25C for 3 hours. The phases are separated and the aqueous phase is washed successively with n-butanol (10 mL) and toluene (10 ML). Then 45 ML OF toluene and 10% aqueous solution of potassium carbonate are added until the aqueous phase pH 10 is reached. The phases are separated and the aqueous phase is extracted with toluene (10 mL). The combined organic phases are evaporated to dryness under vacuum, yielding 4.80 g (85%) of the product of the title as a light yellow oil., 5631-96-9

As the paragraph descriping shows that 5631-96-9 is playing an increasingly important role.

Reference£º
Patent; LABORATORIOS VITA, S.A.; WO2005/14590; (2005); A2;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.344329-76-6,Tetrahydro-2H-pyran-4-carboxamide,as a common compound, the synthetic route is as follows.

Example 7 A solution of Example B5 (0.090 g, 0.697 mmol) in DCE (3 mL) was treated with oxalyl chloride (0.122 mL, 1.394 mmol), heated at 80¡ã C. for 3 h, cooled to RT and concentrated to dryness. The solid was treated with a solution of Example A4 (0.09 g, 0.348 mmol) and TEA (0.194 mL, 1.394 mmol) in THF (3 mL) and stirred at RT for 2 h. The mixture was treated with satd. NaHCO3, extracted with EtOAc (2*) and the combined organics were washed with brine, dried over Na2SO4, concentrated to dryness and purified via silica gel chromatography (MeOH/DCM) to afford N-((5-((2-acetamidopyridin-4-yl)oxy)-6-methylpyridin-2-yl)carbamoyl)tetrahydro-2H-pyran-4-carboxamide (44 mg, 31percent) as a white solid. 1H NMR (400 MHz, DMSO-d6): delta 10.99 (s, 1H), 10.86 (s, 1H), 10.54 (s, 1H), 8.16 (d, J=5.7 Hz, 1H), 7.89 (d, J=8.8 Hz, 1H), 7.60 (d, J=8.8 Hz, 1H), 7.57 (d, J=2.3 Hz, 1H), 6.61 (dd, J=5.7, 2.5 Hz, 1H), 3.87 (m, 2H), 3.32-3.25 (m, 2H), 2.68 (m, 1H), 2.21 (s, 3H), 2.01 (s, 3H), 1.71 (m, 2H), 1.66-1.54 (m, 2H); MS (ESI) m/z: 414.2 (M+H+)., 344329-76-6

344329-76-6 Tetrahydro-2H-pyran-4-carboxamide 13197203, aTetrahydropyrans compound, is more and more widely used in various fields.

Reference£º
Patent; Deciphera Pharmaceuticals, LLC; Flynn, Daniel L.; Caldwell, Timothy Malcolm; Samarakoon, Thiwanka; Vogeti, Lakshminarayana; Kaufman, Michael D.; Patt, William C.; Ahn, YuMi; US2014/275016; (2014); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

344329-76-6, Tetrahydro-2H-pyran-4-carboxamide is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A solution of tetrahydro-2Hr-pyran-4-carboxamide (11.4 g, 88.3 mmol) in THF (441 mL) was cooled to 0 0C. Lithium aluminum hydride (10.0 g, 265 mmol) was added in six portions over a period of ten minutes. The reaction flask was purged with nitrogen between the additions. When the reaction mixture was no longer bubbling, it was heated at reflux for six hours. The reaction was then cooled to 0 0C, and ethyl acetate was added dropwise until bubbling ceased. Methanol was then added dropwise until bubbling ceased. Water (10 mL), 15percent aqueous sodium hydroxide (10 mL), and water (30 mL) were sequentially added. The organic fraction was decanted off, and the remaining gray solid was washed with chloroform. The combined organic fractions were dried over sodium sulfate, filtered, and concentrated under reduced pressure to provide tetrahydro- 2H-pyran-4-ylmethy lamine .

344329-76-6, 344329-76-6 Tetrahydro-2H-pyran-4-carboxamide 13197203, aTetrahydropyrans compound, is more and more widely used in various fields.

Reference£º
Patent; 3M INNOVATIVE PROPERTIES COMPANY; WO2007/75468; (2007); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

1408168-76-2, Potassium trifluoro(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)borate is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a 4 mL vial was added bis(di-tert-butyl(4-dimethylaminophenyl)phosphine) dichloro-palladium(II) (5.0 mg, 7.0 mumol), Cs2CO3 (137 mg, 0.422 mmol), tert-butyl 4-(5-chloro-6-methoxythieno[3,2-b]pyridin-2-yl)-4-oxobutanoate (50.0 mg, 0.141 mmol), and potassium trifluoro(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)borate (39.8 mg, 0.169 mmol). To the vial was added toluene (0.50 mL) and water (0.10 mL). The vial was degassed with N2 for 5 min. The mixture was heated to 100 C. for 18 h. Upon cooling to RT, the mixture was filtered through CELITE, and the CELITE was washed with EtOAc. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel chromatography (0?75% EtOAc gradient in Hex) to afford tert-butyl 4-(6-methoxy-5-(2-((tetrahydro-2H-pyran-2-yl)oxy) ethyl)thieno[3,2-b]pyridin-2-yl)-4-oxobutanoate. LCMS (C23H32NO6S) (ES, m/z): 450 [M+H]+. 1H NMR (500 MHz, CDCl3) delta 8.45 (s, 1H), 7.80 (s, 1H), 4.71 (s, 1H), 4.26-4.15 (m, 1H), 4.04 (s, 3H), 3.78 (t, J=8.3 Hz, 1H), 3.65-3.42 (m, 4H), 3.33 (t, J=6.3 Hz, 2H), 2.73 (t, J=6.3 Hz, 2H), 1.64-1.48 (m, 6H), 1.46 (s, 9H)., 1408168-76-2

As the paragraph descriping shows that 1408168-76-2 is playing an increasingly important role.

Reference£º
Patent; Merck Sharp & Dohme Corp.; Altman, Michael D.; Cash, Brandon D.; Childers, Matthew Lloyd; Cumming, Jared N.; DeMong, Duane E.; Haidle, Andrew Marc; Henderson, Timothy J.; Jewell, James P.; Larsen, Matthew A.; Lim, Jongwon; Lu, Min; Otte, Ryan D.; Trotter, Benjamin Wesley; US2019/300513; (2019); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

2081-44-9, Tetrahydro-2H-pyran-4-ol is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of tetrahydro-2H-pyran-4-ol (10.0 g) and triethylamine (19.1 mL) in dichloromethane (100 mL) was added dropwise methanesulfonyl chloride (10.7 mL) under ice-cooling. The reaction mixture was stirred at room temperature for 1 hr, and dichloromethane was added. The organic layer was washed with saturated aqueous sodium hydrogen carbonate and saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to give the titlecompound (16.2 g) .XH NMR (400 MHz, CDC13) delta 1.84-1.93 (2H, m) , 2.03-2.08 (2H, m) , 3.04 (3H, s), 3.52-3.58 (2H, m) , 3.92-3.98 (2H, m) , 4.88-4.94 (1H, m) .

2081-44-9, As the paragraph descriping shows that 2081-44-9 is playing an increasingly important role.

Reference£º
Patent; TAKEDA PHARMACEUTICAL COMPANY LIMITED; MATSUMOTO, Shigemitsu; ONO, Koji; TOMINARI, Yusuke; KATOH, Taisuke; MIWA, Kazuhiro; HASUOKA, Atsushi; IMAMURA, Shinichi; WO2013/18929; (2013); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.25637-16-5,4-Bromotetrahydropyran,as a common compound, the synthetic route is as follows.

25637-16-5, Step 1: (4-Fluorophenyl)(tetrahydro-2H-pyran-4-yl)methanolTo a 40 mL vial containing magnesium (0.39 g, 16.1 mmol) in THF (15 mL) was slowly added 4-bromotetrahydro-2H-pyran (PharmaBlock, 1.8 mL, 16.1 mmol) coolingin a water bath as needed. The resulting reaction mixture was stirred at room temperature for 1.5 h and then cooled in a water bath. 4-Fluorobenzaldehyde (Aldrich, 1.2 mL, 10.7 mmol) was added slowly. The resulting orange reaction mixture was removed from the water bath and quenched with sat. NH4C1 after 10 mm. 10% LiC1 solution was added and the mixture was extracted with Et20 (2x). The organic layer was dried over MgSO4,filtered and concentrated. The residue was purified using ISCO silica gel chromatography (80 g column, gradient from 0% to 50% EtOAc/hexanes) to give the title compound (1.12 g, 33%) as a colorless oil. ?H NMR (500 MHz, CDC13) oe 7.31 – 7.27 (m, 2H), 7.08 – 7.02 (m, 2H), 4.37 (dd, J=7.7, 2.4 Hz, 1H), 4.06 – 3.99 (m, 1H), 3.94 – 3.87 (m, 1H), 3.37 (td,J=11.9, 2.2 Hz, 1H), 3.29 (td,J=11.8, 2.3 Hz, 1H), 1.94- 1.87 (m, 2H),1.81 (tdt, J=1 1.6, 7.7, 3.8 Hz, 1H), 1.45 (qd, J=12.3, 4.7 Hz, 1H), 1.36 – 1.27 (m, 1H),1.16 (ddq, J=13.2, 3.9, 2.0 Hz, 1H); LCMS (M+H-H20) = 193.1; HPLC RT = 1.65 mill(Column: Chromolith ODS S5 4.6 x 50 mm; Mobile Phase A: 10:90 MeOH:water with0.1% TFA; Mobile Phase B: 90:10 MeOH :water with 0.1% TFA; Temperature: 40 C;Gradient: 0-100% B over 4 mm; Flow: 4 mL/min).

The synthetic route of 25637-16-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BRISTOL-MYERS SQUIBB COMPANY; NORRIS, Derek J.; DELUCCA, George V.; GAVAI, Ashvinikumar V.; QUESNELLE, Claude A.; GILL, Patrice; O’MALLEY, Daniel; VACCARO, Wayne; LEE, Francis Y.; DEBENEDETTO, Mikkel V.; DEGNAN, Andrew P.; FANG, Haiquan; HILL, Matthew D.; HUANG, Hong; SCHMITZ, William D.; STARRETT, JR, John E.; HAN, Wen-Ching; TOKARSKI, John S.; MANDAL, Sunil Kumar; WO2015/100282; (2015); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.65412-03-5,4-(2-Aminoethyl)tetrahydro-2H-pyran,as a common compound, the synthetic route is as follows.

b) Preparation of N-(4-ethoxy-6-{4-oxo-2[2-(tetrahydro-pyran-4-yl)-ethylamino]-4H-thiazol-5-ylidenemethyl}-quinolin-2-yl)-acetamide A suspension of N-[4-ethoxy-6-(4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-quinolin-2-yl]-acetamide (example 6a, 50 mg, 0.11 mmol) in acetonitrile (1.5 ml) was reacted with diisopropylethyl amine (0.200 ml, 1.15 mmol) and methyl iodide (0.15 ml, 2.3 mmol) at rt for 30 min. The mixture was concentrated to dryness and the residue suspended in acetonitrile (1.5 ml). Diisopropylethyl amine (0.20 ml, 1.15 mmol) and 4-(2-aminoethyl)tetrahydropyran (0.075 ml, 0.58 mmol) were successively added at rt, and the mixture was stirred at rt overnight. The precipitate was collected by suction filtration, an washed with acetronitrile. It was then absorbed on SiO2 and purified on a silica gel column with a 0-10% methanol/ethyl acetate gradient to afford the product N-(4-ethoxy-6-{4-oxo-2[2-(tetrahydro-pyran-4-yl)-ethylamino]-4H-thiazol-5-ylidenemethyl}-quinolin-2-yl)-acetamide as a pale yellow solid (22 mg, 50%). LC-MS m/e 469 (MH+)., 65412-03-5

The synthetic route of 65412-03-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Chen, Li; Chen, Shaoqing; Michoud, Christophe; US2006/63804; (2006); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics